Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
Cognition Therapeutics (NASDAQ: CGTX) has successfully closed a $30 million registered direct offering through the sale of 14.7 million shares of common stock at $2.05 per share to two new fundamental institutional investors, including a leading global investment firm.
The offering, managed by Titan Partners Group, will support the Phase 3 development of zervimesine (CT1812), the company's drug candidate for treating neurodegenerative disorders. CEO Lisa Ricciardi highlighted that this investment validates their positive data in three major age-related degenerative disorders.
The shares were offered under a previously filed and effective S-3 shelf registration statement, with the prospectus available through the SEC website and Titan Partners Group.
Cognition Therapeutics (NASDAQ: CGTX) ha concluso con successo un aumento di capitale registrato da 30 milioni di dollari mediante la vendita di 14,7 milioni di azioni ordinarie a 2,05 dollari per azione a due nuovi investitori istituzionali fondamentali, tra cui una primaria società di investimento globale.
L'operazione, coordinata da Titan Partners Group, sosterrà lo sviluppo di Fase 3 di zervimesine (CT1812), il candidato farmaco dell'azienda per i disturbi neurodegenerativi. La CEO Lisa Ricciardi ha sottolineato che questo investimento conferma i dati positivi ottenuti in tre importanti patologie degenerative legate all'età.
Le azioni sono state offerte in base a una dichiarazione di registrazione S-3 precedentemente depositata ed effettiva; il prospetto è disponibile sul sito della SEC e tramite Titan Partners Group.
Cognition Therapeutics (NASDAQ: CGTX) ha cerrado con éxito una oferta directa registrada de 30 millones de dólares mediante la venta de 14,7 millones de acciones comunes a 2,05 dólares por acción a dos nuevos inversores institucionales fundamentales, incluida una destacada firma de inversión global.
La operación, gestionada por Titan Partners Group, financiará el desarrollo de Fase 3 de zervimesine (CT1812), el candidato farmacológico de la compañía para tratar trastornos neurodegenerativos. La directora ejecutiva Lisa Ricciardi indicó que esta inversión valida sus datos positivos en tres importantes enfermedades degenerativas relacionadas con la edad.
Las acciones se ofrecieron bajo una declaración S-3 previamente presentada y en vigor; el prospecto está disponible en la web de la SEC y a través de Titan Partners Group.
Cognition Therapeutics (NASDAQ: CGTX)는 3,000만 달러 규모의 등록 직접 공모를 성공적으로 마무리했습니다. 이번 공모를 통해 1,470만 주의 보통주를 주당 2.05달러에 두 곳의 신규 기관 투자자(세계적 투자사 포함)에게 매각했습니다.
Titan Partners Group이 주관한 이번 공모는 신경퇴행성 질환 치료를 위한 회사의 후보 약물인 zervimesine (CT1812)의 3상 개발을 지원합니다. CEO 리사 리치아르디는 이 투자가 연령 관련 주요 퇴행성 질환 세 곳에서의 긍정적인 데이터를 입증한다고 강조했습니다.
해당 주식은 사전에 제출되어 효력이 발생한 S-3 선매출 등록서에 따라 제공되었으며, 설명서는 SEC 웹사이트와 Titan Partners Group을 통해 확인할 수 있습니다.
Cognition Therapeutics (NASDAQ: CGTX) a clôturé avec succès une offre directe enregistrée de 30 millions de dollars par la vente de 14,7 millions d'actions ordinaires à 2,05 dollars par action à deux nouveaux investisseurs institutionnels de premier plan, dont une importante société d'investissement mondiale.
Cette opération, gérée par Titan Partners Group, financera le développement en phase 3 de la zervimesine (CT1812), le candidat médicament de la société pour les troubles neurodégénératifs. La PDG Lisa Ricciardi a souligné que cet investissement confirme leurs données positives dans trois principales pathologies dégénératives liées à l'âge.
Les actions ont été offertes en vertu d'une déclaration d'enregistrement S-3 précédemment déposée et en vigueur; le prospectus est disponible sur le site de la SEC et via Titan Partners Group.
Cognition Therapeutics (NASDAQ: CGTX) hat erfolgreich eine registrierte Direktplatzierung über 30 Millionen US-Dollar abgeschlossen, bei der 14,7 Millionen Stammaktien zu 2,05 US-Dollar je Aktie an zwei neue institutionelle Kerninvestoren, darunter eine führende globale Investmentgesellschaft, verkauft wurden.
Die von Titan Partners Group begleitete Platzierung soll die Phase-3-Entwicklung von zervimesine (CT1812) unterstützen, dem Wirkstoffkandidaten des Unternehmens zur Behandlung neurodegenerativer Erkrankungen. CEO Lisa Ricciardi betonte, dass diese Investition die positiven Daten in drei bedeutenden altersbedingten degenerativen Erkrankungen bestätigt.
Die Aktien wurden im Rahmen einer zuvor eingereichten und wirksamen S-3-Registrierung angeboten; der Prospekt ist über die SEC-Website und über Titan Partners Group verfügbar.
- Secured $30 million in new capital from prominent institutional investors
- Investment validates positive clinical data in three neurodegenerative disorders
- Strengthens financial position for Phase 3 development of zervimesine
- Significant dilution with 14.7 million new shares being issued
- Offering price of $2.05 per share may represent a discount to market price
Insights
Cognition secured crucial $30M funding from institutional investors, strengthening financial position for Phase 3 development of zervimesine in neurodegenerative disorders.
Cognition Therapeutics has successfully closed a
The transaction's structure as a registered direct offering is noteworthy, as it typically indicates strong investor interest while avoiding the deeper discounts often associated with traditional public offerings. The
The capital will primarily support Phase 3 development of zervimesine (CT1812), Cognition's lead candidate targeting neurodegenerative disorders. Phase 3 trials represent the final and most capital-intensive stage of clinical development before potential regulatory submission. The company's CEO specifically mentioned that zervimesine is being developed for "three major age-related degenerative disorders," indicating a broad potential application across multiple indications.
For a clinical-stage biotech company without marketed products, securing substantial institutional investment is particularly crucial, as it extends the operational runway and reduces near-term financing risk. The participation of a "preeminent global investment firm" may also lend additional validation to Cognition's technology platform and clinical data generated thus far.
This financing strengthens Cognition's position to advance through the capital-intensive late-stage clinical development process without immediate dilutive financing concerns, potentially allowing the company to reach significant clinical milestones that could drive valuation.
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of
Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.
“We believe that this level of support from leading institutional investors validates our efforts and the positive data we have generated to date in three major age-related degenerative disorders,” stated Lisa Ricciardi, president and CEO of Cognition. “With this additional capital, we look forward to advancing zervimesine for the treatment of serious neurodegenerative disorders.”
The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-268992) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on January 3, 2023. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, which was filed with the SEC and is available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Zervimesine (CT1812)
Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to receptors on the surface of neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. Zervimesine has been shown to interrupt the toxic effects of Aβ and ɑ-synuclein, which may slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB. Zervimesine has been generally well tolerated in clinical studies to date.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START study (NCT05531656) in early Alzheimer’s disease is ongoing with
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom and our expectations regarding the development programs for zervimesine, are forward-looking statements. These statements, including statements relating to the expected use of proceeds from and impact of the offering involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com | |
This press release was published by a CLEAR® Verified individual.
FAQ
How much did Cognition Therapeutics (CGTX) raise in their latest offering?
What will CGTX use the $30 million offering proceeds for?
Who were the investors in Cognition Therapeutics' September 2025 offering?
Who was the placement agent for CGTX's $30 million offering?
How many shares did Cognition Therapeutics issue in the September 2025 offering?
